Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.

Neurol Clin PractSep 11, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Soheil Rahmati, Mohammadreza Alinejadfard, Yasaman Zarinfar et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of intravenous thrombolysis (IVT) administered beyond 4.5 hours in patients selected by imaging. Involving 4,944 patients, the study found that extended IVT (4.5-24 hours) significantly improved the odds of achieving excellent functional outcomes (OR: 1.43) compared to standard care, despite an increased risk of symptomatic intracranial hemorrhage (OR: 2.51).

Key findings

  • Extended IVT improved excellent functional outcomes (OR: 1.43) compared to standard care.
  • Good functional outcomes were also higher with extended IVT (OR: 1.25).
  • Recanalization rates were significantly better with extended IVT (OR: 3.28).
  • IVT increased the risk of symptomatic intracranial hemorrhage (OR: 2.51).

Why it matters

The findings suggest that extending the treatment window for IVT in selected patients can lead to better functional outcomes, which is crucial for improving patient quality of life after an acute ischemic stroke.

Source

PubMed · PMID 42727034

Published in Neurol Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.